VolitionRx Limited Announces Pricing of $6.0 Million Underwritten Public Offering of Common Stock and Common Stock Warrants

Core Viewpoint - VolitionRx Limited has announced a public offering of 11,550,000 shares of common stock and warrants, aiming to raise approximately $6.0 million in gross proceeds before expenses [1][3]. Offering Details - The public offering price is set at $0.52 per share, with each warrant priced at $0.01, and an exercise price of $0.60 per share [1]. - The underwriter has a 30-day option to purchase an additional 1,732,500 shares and warrants to cover overallotments [2]. - If the warrants are fully exercised, the additional gross proceeds could reach approximately $6.9 million [3]. Use of Proceeds - The net proceeds from the offering will be utilized for research, product development, clinical studies, commercialization, working capital, and potential strategic acquisitions [4]. Company Overview - Volition is a multinational company focused on advancing epigenetics, aiming to improve early detection and monitoring of diseases [8]. - The company is developing cost-effective blood tests for various diseases, including certain cancers and conditions associated with NETosis [9]. - Research and development activities are primarily based in Belgium, with additional offices in the U.S. and London [10].